Plain-English translation of NCT06928675 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Researchers are studying a substance called cell-free DNA (cfDNA) that naturally circulates in blood and may contribute to inflammation and clotting. This trial will collect blood samples and samples from clots removed during emergency stroke treatment to understand how cfDNA behaves in different types of stroke and whether it affects treatment outcomes.
Currently, doctors don't fully understand what role cell-free DNA plays in stroke or how it might affect a patient's response to emergency clot-removal procedures. This research could help doctors better predict which patients will benefit most from treatment and may lead to new ways to improve stroke outcomes.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have blood samples collected during your emergency stroke care, and researchers would also collect a small sample of the clot that is removed during your thrombectomy procedure. These samples would be analyzed to measure levels of cell-free DNA and understand how it relates to your stroke type and treatment response. There are no additional visits required beyond your standard emergency stroke care.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Switzerland
Enrollment target
~200 participants
Started
March 2025
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gerrit Grosse, PD Dr. Dr.
University Hospital, Basel, Switzerland
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.